Xellia Pharms Aps Company Profile
✉ Email this page to a colleague
What is the competitive landscape for XELLIA PHARMS APS, and when can generic versions of XELLIA PHARMS APS drugs launch?
XELLIA PHARMS APS has fourteen approved drugs.
There are eight US patents protecting XELLIA PHARMS APS drugs.
There are fifty patent family members on XELLIA PHARMS APS drugs in thirty countries and twenty-six supplementary protection certificates in nine countries.
Summary for Xellia Pharms Aps
International Patents: | 50 |
US Patents: | 8 |
Tradenames: | 9 |
Ingredients: | 9 |
NDAs: | 14 |
Drugs and US Patents for Xellia Pharms Aps
International Patents for Xellia Pharms Aps Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Brazil | 112020003862 | ⤷ Subscribe |
Canada | 3070660 | ⤷ Subscribe |
China | 111093625 | ⤷ Subscribe |
Costa Rica | 20170234 | ⤷ Subscribe |
Japan | 6797795 | ⤷ Subscribe |
Philippines | 12017500720 | ⤷ Subscribe |
Singapore | 11201703568W | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Xellia Pharms Aps Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1280520 | 122015000021 | Germany | ⤷ Subscribe | PRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720 |
1115417 | 22/2006 | Austria | ⤷ Subscribe | PRODUCT NAME: DAPTOMYCIN; REGISTRATION NO/DATE: EU/1/05/328/001 UND 002 20060119 |
1280520 | 92678 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: TOBRAMYCINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE. FIRST REGISTRATION: 20110725 |
1115417 | CA 2006 00018 | Denmark | ⤷ Subscribe | PRODUCT NAME: DAPTOMYCIN |
0620232 | SPC/GB02/002 | United Kingdom | ⤷ Subscribe | A SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB02/002 GRANTED TO MERCK SHARP + DOHME, CORP IN RESPECT OF THE PRODUCT CASPOFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE, WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 5919 DATED 30 OCTOBER 2002 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 24 OCTOBER 2016. |
1115417 | SPC/GB06/024 | United Kingdom | ⤷ Subscribe | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021. |
0788511 | SPC/GB08/036 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.